Ablynx NV (ABLX) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 5 PAGES: 35

Ablynx NV (Ablynx) is a biopharmaceutical company engaged in the discovery and development of Nanobodies, for the treatment of serious and life-threatening human diseases. Nanobodies are a novel class of antibody-derived therapeutic proteins, which have the advantages of conventional antibody along with the key features of small molecule drugs. Ablynx possesses the intellectual property rights for the commercialization of Nanobodies based products. The company's product pipeline consists of over 20 Nanobody-based therapeutic candidates. It is developing products in cardiovascular, inflammation, musculoskeletal, neurology, pulmonary and oncology therapeutic areas.

Ablynx NV Key Recent Developments

Aug 25, 2010 Ablynx Reports Net Loss Of EUR15.3 Million For H1 2010
Jul 27, 2010 Ablynx's Chief Scientific Officer Debbie Law Resigns
Jul 05, 2010 Ablynx Receives EUR1.5 Million In Grants
Jun 22, 2010 Ablynx Expands Into New R&D Facilities In Belgium
Jun 22, 2010 Ablynx Moves Into New R&D Facilities In Belgium

This comprehensive SWOT profile of Ablynx NV provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services an

More Info
									                   Ablynx NV (ABLX) - Financial and Strategic Analysis Review

       Reference Code: GDME6397FSA                                                                                      Publication Date: AUG 2010

       Technologiepark 21                          Phone            +32 9 2620000                         Revenue           30 (million EUR)
       Ghent/Zwijnaarde                            Fax              +32 9 2620001                         Net Profit        -20 (million EUR)
       9052                                        Website          www.ablynx.com                        Employees         230
       Belgium                                     Exchange         ABLX [Euronext Brussels]              Industry          Medical Equipment

      Company Overview
       Ablynx NV (Ablynx) is a biopharmaceutical company engaged in the discovery and development of Nanobodies, for the treatment
       of serious and life-threatening human diseases. Nanobodies are a novel class of antibody-derived therapeutic proteins, which
       have the advantages of conventional antibody along with the key features of small molecule drugs. Ablynx possesses the
       intellectual property rights for the commercialization of Nanobodies based products. The company's product pipeline consists of
       over 20 Nanobody-based therapeutic candidates. It is developing products in cardiovascular, inflammation, musculoskeletal,
       neurology, pulmonary and oncology therapeutic areas.

      Key Executives                                                                SWOT Analysis
                    Name                                   Title                    Ablynx NV, SWOT Analysis
      Edwin Moses                          Chairman                                 Strengths                           Weaknesses

      Steven Bunting                       Director
                                                                                    Expanding Market Share in           Decrease in Cash Position
      Geert Cauwenbergh                    Director                                 Sector
      Denis Lucquin                        Director                                                                     Negative Operating Margin
                                                                                    Nanobody Technology
      Mats Pettersson                      Director
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData
                                                                                    Opportunities                       Threats
      Share Data
      Ablynx NV                                                                     Changing Demographics               Rapid Technological Change
       Share Price (EUR) as on 27-Aug-2010                                7.20
                                                                         -0.54      Strategic Collaborations            Industry Consolidation
       EPS (EUR)
                                                                                                                        Challenges
       Market Cap (million EUR)                                            266

       Enterprise Value (million EUR)                                      221

       Shares Outstanding (million)                                            37   Source: Annual Report, Company Website, Primary and Secondary Research
       Source: Annual Report, Company Website, Primary and Secondary Research       GlobalData
       GlobalData

      Financial Performance                                                         Recent Developments
                                                       
								
To top